Opinion|Videos|May 23, 2025
CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.
Advertisement
Future Directions in HIV Treatment
Key Themes:
- Treatment Evolution: Continuous improvement in HIV medications regarding efficacy, tolerability, and convenience
- Long-Acting Formulations: Development of oral, subcutaneous, intramuscular, and intravenous options
- Combination Products: Future devices potentially combining HIV treatment/prevention with contraception or sexually transmitted infection prevention
- HIV Prevention: New preventive therapies potentially effective for 1 to 2 years
Notable Insights from Dr Sharon Walmsley:
- Long-acting therapies help “demedicalize” HIV by reducing medication frequency.
- New challenges in adherence emerge with transition from daily to weekly or monthly dosing schedules.
- HIV treatment advances have informed approaches to other infectious diseases, including COVID-19 and Mpox.
- Despite prevention advances, questions remain about whether to continue vaccine development efforts given limited success to date.
Advertisement
Related to this article
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
5